Finafloxacin/AL 817

Drug Profile

Finafloxacin/AL 817

Alternative Names: AL-60371/AL-817; AL-817/AL-60371; AL-817/finafloxacin

Latest Information Update: 19 Apr 2016

Price : $50

At a glance

  • Originator Alcon
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Otitis media

Most Recent Events

  • 19 Apr 2016 No recent reports on development identified - Phase-II for Otitis media in USA (Otic)
  • 01 Aug 2014 Alcon terminates phase II trial in Otitis media in USA, due to a management decision (NCT01908803)
  • 31 Dec 2013 Phase-II clinical trials in Otitis media in USA (Otic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top